StockData
Kodiak Sciences Inc. logo

Kodiak Sciences Inc. (KOD) company profile

KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$96.80−3.93 (-3.90%)

Close on Nov 17, 2026Market cap $6.08BP/E –Yield –

About Kodiak Sciences

Biological Products, (No Diagnostic Substances), SIC 2836

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on preventing and treating leading causes of blindness. Utilizing its proprietary Antibody Biopolymer Conjugate platform, the company designs therapeutics for patients with retinal vascular diseases and ocular inflammation. Its pipeline includes tarcocimab tedromer, an investigational anti-VEGF therapy undergoing Phase 3 clinical evaluation for conditions such as diabetic retinopathy and wet age-related macular degeneration. Kodiak is also advancing KSI-501, a bispecific therapy targeting interleukin-6 and VEGF, and KSI-101 for macular edema secondary to inflammation. Additionally, the company develops expanded conjugate technologies and digital health platforms.

The company operates globally, retaining worldwide rights to develop, manufacture, and commercialize its investigational medicines. Its infrastructure includes Ursus, a custom-designed, commercial-scale drug substance manufacturing facility commissioned in partnership with Lonza. Kodiak conducts multicenter clinical trials across various international study sites. The provided text does not state the company's specific headquarters location.

Summary of the business section of Kodiak Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Kodiak Sciences Inc.
Founded
2009
Headquarters
Palo Alto, CA
Address
1250 Page Mill Rd 94304
Phone
(650) 281-0850
Website
kodiak.com
Employees
124, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
KOD
Exchange
Nasdaq
IPO date
Oct 5, 2018
Shares outstanding
63M, Aug 6, 2026
Public float
$121.60M, Jun 28, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1468748
CUSIP
50015M109
ISIN
US50015M1099
FIGI
BBG00BVR0D02
Share class FIGI
BBG00BVR0D11
LEI
254900IXI5NI8C9OQE24
EIN
27-0476525

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Victor PerlrothChairman and CEO, Director3,732,242
John A. BorgesonChief Financial Officer211,930
Julian BakerDirector19,221,341
Felix BakerDirector15,455,507
Brothers Life Sciences LP BakerDirector18,358,772
Bros. Advisors (GP) LLC BakerDirector18,373,116
667, L.P.Director1,669,727
Bros. Advisors Lp BakerDirector20,424,859
Taiyin YangDirector20,000
Richard S. LevyDirector250
Robert ProfusekDirector10,000
Bassil I. DahiyatDirector–
Charles A. BancroftDirector25,948

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.50M$24.35M$1.62M$391–
FY2024$1.99M$11.28M$1.36M$12–
FY2023$2.73M-$830.47K$1.54M$4–
FY2022$3.00M-$118.83M$1.57M$8–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Victor Perlroth, M.D
Chief Executive Officer and Chairman of the Board
$792.50K$923.03K$772.82K$10.87K$2.50M+26%
John A. Borgeson
Executive Vice President, Chief Financial Officer and Secretary
$552.97K$678.70K$373.32K$10.87K$1.62M+19%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 5, 2018
Offer price
$10.00
Securities offered
9,000,000
Gross proceeds
$90.00M
Exchange
Nasdaq
First trading day
Oct 4, 2018
First-day close
$10.16+1.6%
Lock-up ends (est.)
Apr 2, 2019

“The initial public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 124 employees worldwide, of whom 10 were based outside of the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 10, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 5, 2018IPOInitial public offering priced (424B4 prospectus)
Oct 1, 2018ListingRegistration of securities on an exchange (Form 8-A)
Jul 28, 2009Name changeName changed from Oligasis, LLC to Kodiak Sciences Inc.

See a number that looks wrong?